FDA: Watch for dosing errors with Zerbaxa
from Pharmacy Practice News
The U.S. Food and Drug Administration has issued a warning to healthcare professionals about the risk for dosing errors with the antibacterial drug combination ceftolozane/tazobactam (Zerbaxa, Cubist) due to confusion about the drug strength displayed on the vial and carton labeling. Zerbaxa is a combination product consisting of ceftolozane, a cephalosporin antibacterial drug, and tazobactam, an inhibitor of certain β-lactamase enzymes. Zerbaxa’s vial label was approved initially with a strength that reflects each individual active ingredient (1 g/0.5 g); however, the product is dosed based on the sum of these ingredients (1.5 g).
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063